EUVIMEDEUVIMED entdecken
Open Access

Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression

Taylor M Triolo iD, Jay M Sosenko, David Cuthbertson, Richard A Oram, Hemang M Parikh, Andrea K Steck, Emily K Sims, Laura M Jacobsen, Brandon Nathan, Erin L Templeman, Suna Onengut-Gumuscu, Carmella Evans-Molina und 4 weitere

Diabetes · 2026

DOI: 10.2337/db25-0711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2026. Verfasst von Taylor M Triolo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Genetic Predisposition to Disease. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin secretion varies widely in preclinical type 1 diabetes. To understand the pathogenesis of this metabolic heterogeneity, we asked whether genetic predisposition to type 2 diabetes, quantified by a type 2 diabetes genetic risk score (T2D-GRS), modulates β-cell function and disease progression in individuals at risk of type 1 diabetes. We analyzed 4,324 islet autoantibody–positive TrialNet Pathway to Prevention participants with genome-wide genotyping and oral glucose tolerance testing. Both T2D-GRS and the type 1 diabetes genetic risk score 2 (T1D-GRS2) differed significantly across five previously described groups defined by C-peptide area under the curve (AUC; a measure of insulin secretion). The highest C-peptide AUC group, compared with the lowest, had significantly higher T2D-GRS, lower T1D-GRS2, higher BMI z-score, greater insulin resistance, older age, and lower prevalence of male participants; multiple islet autoantibody positivity; and IA-2 or insulin autoantibody positivity. Progression to clinical (stage 3) type 1 diabetes was significantly associated with T1D-GRS2 across all groups and with T2D-GRS in all but the lowest C-peptide AUC group. In conclusion, type 2 diabetes genetic burden shapes metabolic heterogeneity and accelerates progression in preclinical type 1 diabetes. These results support the evaluation of type 2 diabetes–related mechanisms as targets to improve the prediction and prevention of type 1 diabetes. Article Highlights Heterogeneity in β-cell function is a barrier to precision medicine in type 1 diabetes. We asked whether type 2 diabetes–associated genes influence insulin secretion and progression to clinical type 1 diabetes in autoantibody-positive individuals. A type 2 diabetes genetic risk score was associated with higher C-peptide area under the curve (AUC) and increased clinical type 1 diabetes risk in all but the lowest C-peptide AUC subgroup. Addressing type 2 diabetes mechanisms could improve type 1 diabetes prediction and prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Genetic Predisposition to DiseaseHumansDisease ProgressionC-PeptideFemaleMaleAdultAutoantibodiesPolymorphism, Single NucleotideInsulin SecretionMiddle AgedRisk FactorsInsulin-Secreting CellsInsulin

Substanzen

C-PeptideAutoantibodiesInsulin

Autor:innen und Institutionen

  • Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL.
  • Health Informatics Institute, University of South Florida, Tampa, FL.
  • University of Exeter, Exeter, U.K.
  • Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
  • Division of Pediatric Endocrinology, University of Florida, Gainesville, FL.

ORCID-Profile: Taylor M Triolo, Maria J Redondo

Förderung

  • NIDDK NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Triolo, T. M., Sosenko, J. M., Cuthbertson, D., Oram, R. A., Parikh, H. M., Steck, A. K., Sims, E. K., Jacobsen, L. M., Nathan, B., Templeman, E. L., Onengut-Gumuscu, S., Evans-Molina, C., Rich, S. S., Atkinson, M. A., Redondo, M. J., & Type 1 Diabetes TrialNet Study Group* (2026). Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression. Diabetes. https://doi.org/10.2337/db25-0711

Vancouver

Triolo TM, Sosenko JM, Cuthbertson D, Oram RA, Parikh HM, Steck AK, et al. Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression. Diabetes. 2026. doi:10.2337/db25-0711

BibTeX
@article{Triolo2026,
  author = {Triolo, Taylor M and Sosenko, Jay M and Cuthbertson, David and Oram, Richard A and Parikh, Hemang M and Steck, Andrea K and Sims, Emily K and Jacobsen, Laura M and Nathan, Brandon and Templeman, Erin L and Onengut-Gumuscu, Suna and Evans-Molina, Carmella and Rich, Stephen S and Atkinson, Mark A and Redondo, Maria J and Type 1 Diabetes TrialNet Study Group*, Type 1 Diabetes TrialNet Study Group*},
  title = {Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression},
  journal = {Diabetes},
  year = {2026},
  doi = {10.2337/db25-0711}
}
Kostenlos starten →